Nabriva Therapeutics Plc Profit Margin

The latest profit margin for NBRV is -153.1% as of March 2023. That compares with -144.38% in the prior-year period — down 6.0% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Nabriva Therapeutics Plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, NBRV's profit margin moved from -144.38% to -153.1% — a 6.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nabriva Therapeutics Plc's valuation or profitability profile.

Against Healthcare companies, NBRV currently prints -153.1% for profit margin, while the sector average sits near 9.48%. That is roughly 1714.8% below the sector mean. Large gaps often invite a closer look at Nabriva Therapeutics Plc's growth, margins, and balance sheet.

Profit Margin shows how effectively Nabriva Therapeutics Plc converts resources into returns. At -153.1%, NBRV may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -144.38% in the prior-year period — down 6.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NBRV's profit margin (-153.1%), review year-over-year change from -144.38%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.